Federal Pharmaceuticals (03933): Levofloxacin eye drops passed the marketing approval of the State Drug Administration of China

Zhitong Financial App News, Federal Pharmaceutical (03933) announced that the levofloxacin eye drops (specification: 0.488% (5ml: 24.4mg)) declared by the Zhongshan Branch of Zhuhai Federal Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the Company, passed the marketing approval of the China State Drug Administration. Drug approval number: Sinopharm Standard H20256135.

Levofloxacin is a third-generation quinolone antibiotic. It inhibits bacterial DNA synthesis by inhibiting the activity of bacterial DNA rotase and topoisomerase IV, and has significant antibacterial activity against various gram-positive bacteria and gram-negative bacteria. Levofloxacin eye drops have characteristics such as a broad antibacterial spectrum and strong antibacterial effect. They are widely used in clinical applications, and can be used in the treatment of blepharitis, blepharitis, dacryocystitis, conjunctivitis, blepharitis, keratitis, and sterile therapy during the perioperative period of ophthalmology. Currently, levofloxacin eye drops are Class A drugs in the National Medical Insurance Catalogue (2024 edition).

This approval will further expand the layout of federal pharmaceuticals' ophthalmology products and strengthen the company's dominant position in the field of ophthalmic anti-infective treatment. The company will continue to work to promote the development of new products and provide comprehensive and high-quality clinical medication solutions, which is expected to generate greater benefits for the company and its shareholders.